Nuwellis, Inc. Set to Announce Second Quarter Financials
Nuwellis, Inc. (Nasdaq: NUWE), a dedicated medical technology company, is gearing up to share its financial results for the second quarter of 2025 on August 12, 2025. This announcement is highly anticipated among stakeholders and industry experts alike, as the company continues to innovate in the field of fluid management.
Conference Call and Webcast
The company will host a conference call at 9:00 AM ET on the day of the announcement, providing an opportunity for a detailed discussion on financial performance and strategic updates. This interactive session promises to deliver insights into Nuwellis' operations and future directions as they address the challenges faced by patients suffering from fluid overload.
How to Participate
To participate in the conference call, interested parties can dial in to 1-800-245-3047 for U.S. callers or 1-203-518-9765 for international guests. The call will also feature a unique conference ID: NUWEQ2, ensuring an organized experience for all participants. Beyond the live session, an audio archive will be made accessible on the Investors page of the Nuwellis website for those unable to attend the live event.
About Nuwellis, Inc.
Nuwellis, Inc. is on a mission to transform the lives of patients afflicted by fluid overload. Their focus centers on the Aquadex SmartFlow® system, designed for ultrafiltration therapy, which represents a significant advancement in treating conditions linked to fluid retention. With its headquarters in Minneapolis and a subsidiary in Ireland, Nuwellis operates with a global perspective, leveraging innovation and collaboration to impact patient care positively.
Innovative Treatment Solutions
The Aquadex SmartFlow system provides a clinically proven approach for managing hypervolemia, a condition characterized by excessive fluid in the body. This technology enables healthcare providers to safely remove excess fluids from patients, offering comfort and relief when traditional treatments fall short. The system is suitable for both adult and pediatric patients, ensuring it meets a range of clinical needs.
Advancing Patient Care with Technology
Nuwellis is committed to continuous improvement and advancement in medical technology. By prioritizing patient outcomes, they aim to refine their approaches and enhance the efficacy of their products. Ongoing research and development efforts enrich their therapeutic options, demonstrating their commitment to being at the forefront of medical innovation.
Contact Information
Investors:
Robert Scott
Chief Financial Officer
ir@nuwellis.com
Media:
Leah McMullen
Director of Communications
leah.mcmullen@nuwellis.com
Frequently Asked Questions
What is the primary focus of Nuwellis, Inc.?
Nuwellis, Inc. focuses on providing innovative solutions for patients suffering from fluid overload through their Aquadex SmartFlow system.
When will Nuwellis announce its financial results?
Nuwellis is set to announce its second quarter financial results on August 12, 2025.
How can I access the conference call?
You can access the conference call by dialing 1-800-245-3047 in the U.S. or 1-203-518-9765 internationally.
What is the Aquadex SmartFlow system?
The Aquadex SmartFlow system is a medical technology designed for ultrafiltration therapy to manage fluid overload in patients.
What is the contact information for Nuwellis investor relations?
The investor relations contact is Robert Scott, Chief Financial Officer, and can be reached at ir@nuwellis.com.
